Inclusion Criteria:

- < 21 years of age at original diagnosis

- histological verification of low grade glioma (glial tumors, neuronal tumors or
chiasmatic-hypothalamic tumor) at original diagnosis

- evidence of tumor recurrence or progression by MRI or contrast CT

- Karnofsky and Lansky performance status of 0,1 or 2

- life expectancy of greater than or equal to 2 months

- adequate organ and bone marrow function within 7 days of starting treatment with
Vinblastine

- absolute neutrophil count (ANC)> 1000/uL

- platelet count > 100,000/uL (transfusion independent)

- serum creatinine < 1.5 x normal for age

- written informed consent signed by subject and/or subject's parent/legal guardian

Exclusion Criteria:

- not recovered from the acute toxic effects of all prior chemotherapy, immunotherapy
or radiotherapy

- chemotherapy within 2 weeks of entry in study (4 weeks if prior nitrosourea was used)

- less than 7 days since the completion of therapy with a biologic agent

- less than 2 months since cranial/spinal radiation

- receiving a stable dose of dexamethasone for less than one week